CN103764132B - 线粒体靶向的抗氧化剂的口服制剂及其制备和用途 - Google Patents

线粒体靶向的抗氧化剂的口服制剂及其制备和用途 Download PDF

Info

Publication number
CN103764132B
CN103764132B CN201280027129.0A CN201280027129A CN103764132B CN 103764132 B CN103764132 B CN 103764132B CN 201280027129 A CN201280027129 A CN 201280027129A CN 103764132 B CN103764132 B CN 103764132B
Authority
CN
China
Prior art keywords
compound
skq1
formula
integer
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280027129.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103764132A (zh
Inventor
M.V.斯库拉彻夫
V.P.斯库拉彻夫
A.A.扎姆亚特宁
E.S.埃夫雷莫夫
V.N.塔什利特斯基
R.A.齐诺夫金
M.V.埃戈罗夫
L.T.弗里德霍夫
O.Y.普勒图什基纳
A.A.安德里夫-安德里夫斯基
T.V.齐内维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitotech SA
Original Assignee
Mitotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitotech SA filed Critical Mitotech SA
Publication of CN103764132A publication Critical patent/CN103764132A/zh
Application granted granted Critical
Publication of CN103764132B publication Critical patent/CN103764132B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5435—Cycloaliphatic phosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B11/00—Diaryl- or thriarylmethane dyes
    • C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
    • C09B11/10—Amino derivatives of triarylmethanes
    • C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B57/00—Other synthetic dyes of known constitution
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
CN201280027129.0A 2011-06-03 2012-06-04 线粒体靶向的抗氧化剂的口服制剂及其制备和用途 Expired - Fee Related CN103764132B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161492940P 2011-06-03 2011-06-03
US61/492,940 2011-06-03
US61/492940 2011-06-03
PCT/US2012/040711 WO2012167236A1 (en) 2011-06-03 2012-06-04 Oral formulations of mitochondrially-targeted antioxidants and their preparation and use

Publications (2)

Publication Number Publication Date
CN103764132A CN103764132A (zh) 2014-04-30
CN103764132B true CN103764132B (zh) 2017-04-12

Family

ID=47259946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280027129.0A Expired - Fee Related CN103764132B (zh) 2011-06-03 2012-06-04 线粒体靶向的抗氧化剂的口服制剂及其制备和用途

Country Status (10)

Country Link
US (2) US9192676B2 (https=)
EP (1) EP2714024B1 (https=)
JP (2) JP6448366B2 (https=)
CN (1) CN103764132B (https=)
AU (1) AU2012261854B2 (https=)
BR (1) BR112013030605A2 (https=)
CA (1) CA2837437C (https=)
EA (1) EA031399B1 (https=)
ES (1) ES2704064T3 (https=)
WO (1) WO2012167236A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714024B1 (en) * 2011-06-03 2018-10-03 Mitotech SA Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
JP6506177B2 (ja) * 2013-01-22 2019-04-24 ミトテック ソシエテ アノニム ミトコンドリアにターゲティングされた抗酸化剤を含む医薬処方物
WO2015063553A2 (en) * 2013-04-11 2015-05-07 Mitotech S.A. Mitochondrially-targeted timoquinones and toluquinones
EA034726B1 (ru) * 2014-02-25 2020-03-13 Общество С Ограниченной Ответственностью "Митотех" Косметическая композиция на основе митохондриально-адресованных антиоксидантов
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
CA3164227A1 (en) * 2019-12-10 2021-06-17 Mitotech S.A. Polymer matrixes for different compositions of mitochondrially targeted antioxidants
CN116194100A (zh) * 2020-04-03 2023-05-30 米拓科技有限公司 线粒体靶向抗氧化剂在治疗严重炎症中的用途
CN114344274A (zh) * 2022-01-05 2022-04-15 盖茨汉普(武汉)植物应用研究有限公司 一种Mitoq抗氧化硬胶囊配方及制备工艺
WO2025078880A1 (en) * 2023-10-11 2025-04-17 Mitotech S.A. Mitochondria-targeted antioxidants for use in the treatment of cell balloooning-associated diseases, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234326A1 (en) * 2007-04-11 2010-09-16 Skulachev Maxim V Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
US20110053895A1 (en) * 2007-06-29 2011-03-03 Maxim Vladimirovich Skulachev Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538974A (en) 1994-01-27 1996-07-23 Senju Pharamceutical Co., Ltd. Ophthalmic composition for lowering intraocular pressure
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
ATE296305T1 (de) 1997-11-25 2005-06-15 Antipodean Biotechnology Ltd Antioxidantien mit spezifischer wirkung auf mitochondrien
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
CA2397684A1 (en) 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
WO2005033093A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
CN1997403A (zh) 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
WO2006025247A1 (ja) * 2004-08-30 2006-03-09 Kaneka Corporation ミトコンドリア賦活剤
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
EA200900582A1 (ru) 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Фармацевтические композиции для профилактики и лечения глазных патологий
EA200900583A1 (ru) 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Композиция для регенерации, стимуляции роста и адаптации растений к различным стрессовым факторам
EP2145623A4 (en) * 2007-01-29 2010-10-27 Ltd Liability Company Mitotech PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR ACCELERATING THE PROCESS OF WOUND HEALING AND OTHER SURFACE INJURIES
JP5798481B2 (ja) 2008-06-25 2015-10-21 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体
EA201101576A1 (ru) 2009-04-28 2012-04-30 Эдисон Фармасьютикалз, Инк. Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
AU2009347921B8 (en) * 2009-06-10 2014-07-24 Mitotech Sa Pharmaceutical composition for use in medical and veterinary ophthalmology
BR112012011197A2 (pt) * 2009-11-13 2020-10-20 Obschestvo S Ogranichennoi Otvetsvennostyu "Mitotekh" subtâncias farmacêuticas com base em antioxidantes direcionados à mitocôndria
EP2714024B1 (en) * 2011-06-03 2018-10-03 Mitotech SA Oral formulations of mitochondrially-targeted antioxidants and their preparation and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234326A1 (en) * 2007-04-11 2010-09-16 Skulachev Maxim V Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
US20110053895A1 (en) * 2007-06-29 2011-03-03 Maxim Vladimirovich Skulachev Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mitochodria-Targeted Plastoquinone Derivatives as Tools to Interrupt Execution of the Aging Program. 5. SkQ1 Prolongs Lifespan and Prevents Development of Traits of Senescence;V.N.Anisimov et al.;《Biochemistry(Moscow)》;20081231;第73卷(第12期);1329-1342 *
Reactive oxygen species produced in mitochondria are involved in age-dependent changes of hematopoietic and mesenchymal progenitor cells in mice. A study with the novel mitochondria-targeted antioxiadant SkQ1;I.N.Shipounova et al.;《Mechanisms of Ageing and Development》;20100617(第131期);415-421 *

Also Published As

Publication number Publication date
JP6461276B2 (ja) 2019-01-30
EP2714024B1 (en) 2018-10-03
EA201301321A1 (ru) 2014-11-28
ES2704064T3 (es) 2019-03-14
CN103764132A (zh) 2014-04-30
JP2014515407A (ja) 2014-06-30
US9572890B2 (en) 2017-02-21
US20150025043A1 (en) 2015-01-22
JP2018035182A (ja) 2018-03-08
CA2837437A1 (en) 2012-12-06
CA2837437C (en) 2020-12-15
EA031399B1 (ru) 2018-12-28
EP2714024A1 (en) 2014-04-09
BR112013030605A2 (pt) 2016-12-13
AU2012261854B2 (en) 2017-11-16
WO2012167236A1 (en) 2012-12-06
EP2714024A4 (en) 2014-12-31
JP6448366B2 (ja) 2019-01-09
US9192676B2 (en) 2015-11-24
US20160038603A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
CN103764132B (zh) 线粒体靶向的抗氧化剂的口服制剂及其制备和用途
EP3454835B1 (en) Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
US9170257B2 (en) Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
AU2012261854A1 (en) Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
US8815284B2 (en) Bioerodible sustained release drug delivery systems
JP2025114555A (ja) 皮下注射のためのケタミン製剤
EP3478276B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
WO2024151720A1 (en) Compositions of caffeoylspermidine compounds, uses thereof, and supplements of spermidine thereof
TW201717959A (zh) 用於對金屬卟啉進行微粒遞送之調配物及用途
EP4208160A1 (en) Ionic liquid formulations for treating diabetes
CN113197854A (zh) 一种氟康唑三元纳米胶束及其制备方法
WO2024151725A1 (en) Methods of enrichment of caffeoylspermidine compounds, anti-aging properties thereof, and methods of inhibition of histone deacetylases
US20260053750A1 (en) Inhalable compositions of cdk9 inhibitors
Simonelli et al. A RESVERATROL–HYDROGEN SULFIDE DONOR HYBRID AS A MULTI-TARGET THERAPEUTIC STRATEGY FOR ALLERGIC ASTHMA
CN120000589A (zh) 一种阿比特龙脂质体及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170412

CF01 Termination of patent right due to non-payment of annual fee